We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




IV Solution Treats Surgical Blood Volume Loss

By HospiMedica staff writers
Posted on 08 Jan 2008
An intravenous starch solution prevents and treats dangerous loss of blood volume, a condition that sometimes occurs during and after surgery. More...


Voluven, a synthetic starch (6% hydroxyethyl starch) solution that does not dissolve in water, is formed by linked individual starch molecules combined with normal saline (0.9% sodium chloride); the starch solution works by expanding blood volume, restoring some of the blood volume lost during surgery. The starch-enriched plasma draws fluid into the capillaries so that remaining red blood cells can continue to deliver oxygen to the body's tissues.

In clinical trials, Voluven was compared to other approved blood volume expanders. In newborns and infants undergoing major surgery, it was found as safe and effective as an equivalent volume of another approved starch solution expander containing albumin, Hespan, manufactured by B. Braun Medical (Bethlehem, PA, USA). In other trials conducted outside of the United States, Voluven was as safe as other blood volume expanders used in those countries in patients ranging in age from less than two years to 75 years who were undergoing a variety of surgical procedures.

Voluven is not recommended for patients with known abnormal sensitivity to the synthetic starch used in the product; patients experiencing fluid overload; patients with kidney failure not related to low blood volume; patients on dialysis; patients with severe increases in blood levels of sodium or chloride; and patients with intracranial bleeding. Voluven is manufactured by Fresenius Kabi (Bad Homburg, Germany), and has been approved by the U.S. Food and Drug Administration (FDA).

"Massive blood loss is a life-threatening problem. Approval of Voluven provides clinicians with an alternative blood volume product that is safe and effective in a wide range of age groups,” said Jesse L. Goodman, M.D., M.P.H., director of FDA's Center for biologics evaluation and research.


Related Links:
Fresenius Kabi
B. Braun Medical

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Rapid Sepsis Test
SeptiCyte RAPID
New
Monitor/Defibrillator
Zenix
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Health IT

view channel
Photo courtesy of Adobe Stock

Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings

Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.